Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

BTIG starts Sutro Biopharma at buy; PT $19

BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4. Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to...

October 7, 2019

Markets

SVB Leerink ups AMAG Pharma PT to $14 from $9

SVB Leerink raised its price target for AMAG Pharmaceuticals (NASDAQ:AMAG) to $14 from $9 ahead of an FDA advisory committee meeting on Oct. 29. The stock closed at $11.50 on Oct. 4. “Based on our MEDACorp survey of 50...

October 7, 2019

Markets

HCW starts Fulcrum Therapeutics at buy; PT $21

H.C. Wainwright launched coverage of Fulcrum Therapeutics (NASDAQ:FULC) with a “buy” rating and $21 price target. The stock closed at $6.59 on Oct. 2. Fulcrum’s lead program, losmapimod, a p38 alpha/beta MAP kinase...

October 3, 2019

Markets

HCW starts PhaseBio Pharma at buy; PT $18

H.C. Wainwright initiated coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a “buy” rating and $18 price target. The stock closed at $4.03 on Oct. 2. PhaseBio’s Phase 2 candidate, PB2452, which is licensed from...

October 3, 2019

Markets

Stifel starts Fate Therapeutics at buy; PT $27

Stifel launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and $27 price target. The stock closed at $15.47 on Sept. 28. Fate is using its induced pluripotent stem cell (iPSC) platform to develop...

September 30, 2019

Markets

AGP ups OpGen PT to $11.30 from reverse-split adjusted $8

Alliance Global Partners raised its price target for OpGen (NASDAQ:OPGN) to $11 from a reverse-split adjusted $8 after an analysis of its proposed merger with Curetis (Euronext:CURE), an infectious disease molecular...

September 30, 2019

Markets

Roth starts Daxor at neutral; PT $18

Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...

September 30, 2019

Markets

Stifel cuts Concert Pharma to hold; PT to $8 from $18

Stifel downgraded Concert Pharmaceuticals (NASDAQ:CNCE) to “hold” from “buy” and lowered its price target to $8 from $18 after the company reported a Phase 3 trial failure with its AVP-786 drug candidate in Alzheimer’s...

September 27, 2019

Markets

HCW starts Hookipa Pharma at buy; PT $15

H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its proprietary family...

September 27, 2019

Markets

HCW ups Bionomics to buy; PT to 30 cents from 3 cents

H.C. Wainwright upgraded Bionomics (ASX:BNO) to “buy” from “neutral” and raised its price target to 30c (Australian) from three cents after the company announced results of a pharmacokinetics (PK) study of the tablet...

September 26, 2019

Markets

BTIG starts NeuBase Therapeutics at buy; PT $15

BTIG initiated coverage of NeuBase Therapeutics (NASDAQ:NBSE) with a “buy” rating and $15 price target. The stock closed at $6.55 on Sept. 23. NeuBase has developed a modular antisense peptide nucleic acid (PNA)...

September 24, 2019

Markets

AGP starts coverage of 4 cannabis companies at buy

Alliance Global Partners launched coverage of four cannabis companies – Acreage Holdings (CSE:ACRG; OTCQX:ACRGF), GrowGeneration (OTCQX:GRWG), Village Farms International (TSX:VFF) and Green Thumb Industries...

September 19, 2019

Markets

WB starts Axsome Therapeutics at OP; fair value estimate $48

William Blair initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and a fair value estimate of $48. The stock closed at $28.21 on Sept. 17. Axsome Therapeutics is focused on developing...

September 18, 2019

Markets

WB starts Minerva Neurosciences at OP; fair value estimate $26

William Blair launched coverage of Minerva Neurosciences (NASDAQ:NERV) with an “outperform” rating and fair value estimate of $26. The stock closed at $8.11 on Sept. 17. Minerva is developing therapies for mood...

September 18, 2019

Markets

SVB Leerink starts Axonics Modulation at OP; PT $45

SVB Leerink initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with an “outperform” rating and $45 price target. The stock closed at $30.27 on Sept. 16. “To us, Axonics represents a hyper-growth story...

September 17, 2019

Markets

TBIG starts Cellular Biomedicine at buy; PT $19

TBIG launched coverage of Cellular Biomedicine Group (NASDAQ:CBMG) with a “buy” rating and $19 price target. The stock closed at $14.84 on Sept. 16. Cellular has been developing its cGMP grade cell therapy manufacturing...

September 17, 2019

Markets

HCW ups Pluristem PT to $15.50 from $3.50 post reverse split

H.C. Wainwright raised its price target for Pluristem Therapeutics (NASDAQ:PSTI) to $15.50 from $3.50, reflecting a 10-for-1 reverse stock split and promising early results from a Phase 1 study. The stock closed at $4...

September 17, 2019

Markets

Dawson James starts BioCardia at buy; PT $24

Dawson James Securities launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $24 price target. The stock closed at $4.84 on Sept. 16. BioCardia is a developing two different cell therapy systems to...

September 17, 2019

Markets

Roth starts Cellectar Biosciences at buy; PT $11

Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted...

September 13, 2019

Markets

BTIG ups Eidos Therapeutics PT to $56 from $38

BTIG raised its price target for Eidos Therapeutics (NASDAQ:EIDX) to $56 from $38 after a committee of the board unanimously rejected a share exchange offer from its parent company, BridgeBio Pharma, (NASDAQ:BBIO) to...

September 13, 2019

Markets

Analysts up T2 Biosystems price targets

Analysts for Alliance Global Partners and SVB Leerink raised their price targets for T2 Biosystems (NASDAQ:TTOO) following a conference call that updated multiple positive developments. Ben Haynor of AGP writes that the...

September 12, 2019

Markets

WB starts PhaseBio Pharma at OP; risk-adjusted valuation $16

William Blair launched coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with an “outperform” rating and risk-adjusted valuation of $16. The stock closed at $5.04 on Sept. 10. Analyst Matthew Phipps writes that his...

September 11, 2019

Subscribe